Speaker Bios - Inozyme Pharma | Inozyme Pharma Inc.

Axel Bolte, MBA

Co-Founder, President and Chief Executive Officer

Axel Bolte is Inozyme’s Co-Founder, President and Chief Executive Officer. He has served as a member of the company’s Board of Directors since September 2015. Since March 2017, Mr. Bolte has also served as a Managing Member of Healthcare Advisors GmbH, a private healthcare advisory company. Mr. Bolte served as a Venture Partner at HBM Partners AG, a provider of investment advisor services in the life sciences industry, from February 2017 to September 2019, and as an Investment Advisor to HBM Partners AG from March 2003 to January 2017. Mr. Bolte currently serves on the Board of Directors of IVERIC bio, Inc. (formerly known as Ophthotech Corporation), and previously served on the Board of Directors of Allena Pharmaceuticals, Inc., Nabriva Therapeutics plc, and PTC Therapeutics, Inc. Mr. Bolte received a degree in Biochemistry from the Swiss Federal Institute of Technology in Switzerland and an MBA from the University of St. Gallen in Switzerland.

Henric Bjarke

Senior Advisor

Henric Bjarke currently serves as a Senior Advisor to Inozyme. He previously served as the company’s Senior Vice President and Chief Operating Officer. Prior to joining Inozyme, Mr. Bjarke served as Senior Vice President, Chief Commercial Officer, of IVERIC bio, Inc. from September 2015 to April 2017. He also previously served in multiple roles at Alexion Pharmaceuticals, Inc., including as Vice President, Global Metabolic Disorders Franchise, from November 2012 to August 2015 and as Vice President, North America Commercial Operations, from September 2010 to November 2012. Prior to joining Alexion, Mr. Bjarke served in various commercial roles at Watson Pharmaceuticals, Inc., Eyetech Pharmaceuticals, Inc., and Pharmacia Corporation. Mr. Bjarke received a B.A. Sc. in Business Administration and Economics from Uppsala University in Sweden.

Kurt Gunter, M.D.

Chief Medical Officer

Kurt Gunter, M.D., is Chief Medical Officer at Inozyme. He brings to Inozyme over 30 years of expertise in regulatory affairs, clinical development, and government relations. Prior to joining Inozyme, he most recently served as Chief Medical Officer, Cell Therapy, and Head of Regulatory Affairs at Athenex, Inc. Prior to Athenex, Dr. Gunter served as Chief Medical Officer at Kuur Therapeutics, Inc. (formerly Cell Medica), where he headed the medical affairs, clinical operations, and regulatory affairs departments. He also previously held positions of increasing responsibility at Hospira, Inc., including Vice President, Clinical Development, and Global Medical Director for Hematology-Oncology. Before Hospira, Dr. Gunter held positions at Zymequest Inc., ViaCell, Inc., and Transkaryotic Therapies, Inc. While at Transkaryotic Therapies, he played an integral role in the global regulatory strategy for Replagal, an enzyme replacement therapy approved for Fabry disease. He also previously served as President of the International Society for Cellular Therapy, where he played a worldwide leadership role in promoting understanding of the clinical, regulatory, manufacturing, and marketing requirements for the successful development of cell and gene therapies. Prior to his biotech career, Dr. Gunter worked at the U.S. Food and Drug Administration (FDA) as a Medical Officer in the Center for Biologics and was appointed Acting Deputy Director of the Division of Cell and Gene Therapy within the Center for Biologics Evaluation and Research. He also served for five years on the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee. Dr. Gunter earned his M.D. from the University of Kansas School of Medicine and his B.S. in Biological Sciences, with Distinction, from Stanford University. His postdoctoral training included Johns Hopkins University and the U.S. National Institutes of Health.

Yves Sabbagh, Ph.D.

Chief Scientific Officer

Yves Sabbagh, Ph.D., is Inozyme’s Chief Scientific Officer. Dr. Sabbagh brings to Inozyme more than 20 years of experience in rare genetic disorders and mineral metabolism with responsibilities leading to the identification and evaluation of novel therapeutic approaches and translating them into clinical candidates. Prior to joining Inozyme, Dr. Sabbagh served as the Head of Rare Renal and Musculoskeletal Diseases Research at Sanofi S.A. Prior to that executive role, he held scientific roles of increasing responsibility at Sanofi and Genzyme Corporation spanning endocrine, renal, and rare bone diseases, including driving the strategy for bone indications. Prior to his corporate experience, he was an instructor at the Harvard Medical School in the Endocrine unit. Dr. Sabbagh has co-authored more than 30 peer-reviewed publications and book chapters and is a member of several scientific societies. Dr. Sabbagh received a B.S. in Biochemistry from McGill University in Canada, an M.S. in Microbiology from Université Laval in Canada, and a Ph.D. in Biology from McGill University.

Sanjay S. Subramanian, M.S., MBA

Chief Financial Officer

Sanjay Subramanian joined Inozyme as Chief Financial Officer in March 2022. He brings to Inozyme over 20 years of corporate finance, capital markets, and business development expertise. Prior to joining Inozyme, Mr. Subramanian served as Chief Financial Officer and head of corporate development at Ocugen, Inc., where he led the company’s finance, investor relations, and business development functions. At Ocugen, Mr. Subramanian was instrumental in improving its capital structure, raising over $200 million, and leading transformative collaboration. Prior to Ocugen, he held roles of increasing responsibility at Aralez Pharmaceuticals Inc., most recently as Chief Financial Officer, and played a key role in the Aralez’s formative transaction and its listing on Nasdaq and TSX. Mr. Subramanian also previously held positions of increasing responsibility at Bausch Health Companies Inc., including playing a key role in the acquisition, financing, and post-merger integration of Bausch + Lomb Corporation. Before Bausch Health, Mr. Subramanian was part of General Motors Company’s finance leadership rotation program and served as the Managing Director and Treasurer at its Korea division in his last role. He received an MBA from the MIT Sloan School of Management, an M.S. from both the Massachusetts Institute of Technology and The Ohio State University, and a Bachelor of Technology from the Indian Institute of Technology in India.

David Thompson, M.A., M.S., Ph.D.

Senior Advisor

David Thompson, Ph.D., is a Senior Adviser to Inozyme. He previously served as the company’s Senior Vice President and Chief Scientific Officer from 2018 to 2020. Dr. Thompson brings more than 30 years of experience designing and leading research and development programs focused on bone disorders and phosphate regulation. Prior to joining Inozyme, Dr. Thompson was a Founder and President of Azure Biotech Inc., where he was responsible for the development of a novel formulation of lasofoxifene, a non-steroidal selective estrogen receptor modulator used for the prevention and treatment of osteoporosis and the treatment of vaginal atrophy. Previously, Dr. Thompson held executive positions in clinical research and drug development in multiple biopharma companies, including Alexion Pharmaceuticals, Inc. where he led the clinical development of asfotase alfa for the treatment of hypophosphatasia; Pfizer Inc., where he oversaw the osteoporosis research and frailty discovery groups; and Merck Research Labs, where he conducted preclinical work and participated in the early clinical development of alendronate for the treatment of osteoporosis. Dr. Thompson received his M.A. from the University of Montana and his M.S. and Ph.D. from the University of Connecticut.

Mark Kiel, M.D., Ph.D.

Chief Science Officer, Genomenon

Mark Kiel, M.D., Ph.D., is the Founder and Chief Scientific Officer at Genomenon, Inc., an AI-driven genomics company addressing the challenge of connecting pharma researchers with evidence in the genomic literature to help diagnose and treat patients with rare genetic diseases and cancer. He oversees the company’s scientific direction and product development. Dr. Kiel completed his M.D., Ph.D., and Molecular Genetic Pathology Fellowship at the University of Michigan, where his research focused on stem cell biology, genomic profiling of hematopoietic malignancies, and clinical bioinformatics. He received his B.S. in Chemical Engineering from Northwestern University.

Michael A. Levine, M.D.

Professor Emeritus, Pediatrics and Medicine and Chief Emeritus, Division of Endocrinology and Diabetes at the Center for Bone Health at the Children’s Hospital of Philadelphia Research Institute

Michael Levine, M.D., is Chief of the Division of Endocrinology and Diabetes and Director of the Center for Bone Health at The Children’s Hospital of Philadelphia. Dr. Levine holds the Lester Baker Endowed Chair in Pediatric Diabetes. His primary clinical interests are endocrine diseases and genetic disorders that affect bone and mineral metabolism. Dr. Levine has an active laboratory research program that complements and extends his clinical and translational studies. He has identified the molecular basis of several inherited disorders of mineral metabolism, and his research interests extend to the molecular basis for embryological development of the parathyroid glands and disorders of vitamin D metabolism. He is a founding Executive Editor for the Journal of Clinical and Translational Science and an Associate Editor of the Journal of Clinical Endocrinology and Metabolism. He is also a member of numerous professional societies, including the American Society for Bone and Mineral Research, the American Society for Clinical Investigation, the Association of American Physicians, and the American Pediatric Society. Dr. Levine is a Fellow of the American College of Physicians, the American Academy of Pediatrics, and the American College of Endocrinology. He received his M.D. from Drexel University College of Medicine and his B.A. in Bacteriology from Rutgers University.

Wilko Spiering, M.D., Ph.D.

Associate Professor, Division of Internal Medicine and Dermatology, Department of Vascular Medicine, at the University Medical Center Utrecht of Utrecht University

Wilko Spiering, M.D., Ph.D., is as an Internist-Vascular Physician at the Department of Vascular Medicine at University Medical Center (UMC) Utrecht. He founded the Complicated Hypertension Outpatient Clinic and is involved in the Renal Denervation Program at UMC Utrecht. He also has a special outpatient clinic for patients with pseudoxanthoma elasticum (PXE), a rare hereditary disorder of the blood vessels, among other things. His research focuses on obesity-related hypertension, new treatment strategies for hypertension, and the vascular complications and possible treatments for PXE. Dr. Spiering is Chairman of the Internal Medicine Society and Secretary of the Dutch Hypertension Association. Dr. Spiering studied Medicine at Maastricht University in the Netherlands, where he also obtained his Ph.D.